SCHEMBL22939

SCHEMBL22939

COC(=O)[C@H](O)c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.56
ADRB2 P07550 2/20 0.45
ADRB1 P08588 2/20 0.45
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 1/20 0.44
THRB P10828 1/20 0.44
NR1I2 O75469 1/20 0.44
ABCB11 O95342 1/20 0.44
CHRM2 P08172 1/20 0.44
ADRA2A P08913 1/20 0.44
CYP2B6 P20813 1/20 0.44
DRD1 P21728 1/20 0.44
HTR2A P28223 1/20 0.44
SLC6A4 P31645 1/20 0.44
CYP2C19 P33261 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRK1 P41145 1/20 0.44
HTR2B P41595 1/20 0.44
KCNH2 Q12809 1/20 0.44
P2RY12 Q9H244 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3685278 1.00 CASP1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A
SCHEMBL29572218 1.00 CASP1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A
SCHEMBL29572016 1.00 CASP1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A
SCHEMBL253615 1.00 CASP1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A
SCHEMBL31506886 1.00 CASP1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A
Methylene Chloride SCHEMBL28084097 0.95 CASP1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A
SCHEMBL30536648 0.88 CASP1 (0.52) CASP1ADRB2ADRB1THRBNR1I2
SCHEMBL9890698 0.86 CASP1 (0.44) CASP1ALDH1A1KMT2ATHRBNR1I2
SCHEMBL27962041 0.86 CYP1A2 (0.46) CASP1ALDH1A1KMT2ACYP2D6NFKB1
SCHEMBL6487230 0.83 ALDH1A1 (0.56) CASP1ADRB2ADRB1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116655652-A New synthesis method of clopidogrel 宿迁盛基医药科技有限公司 2023-08-29 CN claimed
CN-103524528-A Improved preparation method of II-type clopidogrel hydrogen sulfate crystal JILIN BROADWELL PHARMACEUTICAL CO LTD 2014-01-22 CN claimed
EP-2970112-B1 PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2025-03-12 EP disclosed
US-20250066381-A1 ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS MOLECULES & MATERIALS (KR) 2025-02-27 US disclosed
US-20250002466-A1 PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF METROCHEM API PVT LTD 2025-01-02 US disclosed
EP-2968210-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY BIO PHARM SOLUTIONS CO LTD (KR) 2024-09-11 EP disclosed
CN-118308316-A Biocatalysis asymmetric reaction reductase and application thereof 湖州师范学院 2024-07-09 CN disclosed
CN-117924313-A Tetrahydrothienopyridine derivative and preparation method and application thereof 仁合益康集团有限公司 2024-04-26 CN disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
CN-112778371-B Thienopyridine derivative and preparation method and application thereof 华创合成制药股份有限公司 2024-01-30 CN disclosed
US-11834413-B2 Antiplatelet drugs and uses thereof SHANGHAI CUREGENE PHARMACEUTICAL CO LTD. (CN) 2023-12-05 US disclosed
US-20080311636-A1 Method for Producing Optically Active Alpha-Hydroxycarboxylic Acid DAIICHI FINE CHEMICAL CO., LTD. (JP) 2008-12-18 US disclosed
US-20080311636-A1 Method for Producing Optically Active Alpha-Hydroxycarboxylic Acid DAIICHI FINE CHEMICAL CO., LTD. (JP) 2008-12-18 US disclosed
JP-2008182984-A METHOD FOR PRODUCING (R)-2-CHLOROMANDELIC ACID METHYL ESTER OKAYAMA UNIV 2008-08-14 JP disclosed
EP-1930441-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE -HYDROXYCARBOXYLIC ACID Daiichi Fine Chemical Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930441-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE -HYDROXYCARBOXYLIC ACID Daiichi Fine Chemical Co., Ltd. (JP) 2008-06-11 EP disclosed
WO-2007078176-A1 THE METHOD OF MAKING OPTICALLY ACTIVE 2-CHLOROMANDELIC ACID ESTERS AND 2-CHLOROMANDELIC ACIDS BY ENZYMATIC METHOD ENZYTECH, LTD. (KR) 2007-07-12 WO disclosed
CN-1314906-A Salts of paroxetine SMITHKLINE BEECHAM PLC (GB) 2001-09-26 CN disclosed
EP-0816316-A1 PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1998-01-07 EP disclosed
US-5614641-A USING A PHOSPHINO-CONTAINING RUTHENIUM COMPLEX AS CATALYST ELF AQUITAINE (FR) 1997-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311636-A1 Method for Producing Optically Active Alpha-Hydroxycarboxylic Acid PCCA, HCAR1, HCAR2 CASP1 333/4885ADRB2 4593/4885ADRB1 4142/4885
US-11834413-B2 Antiplatelet drugs and uses thereof PFKP, GP6, PF4 CASP1 3907/4885ADRB2 624/4885ADRB1 764/4885
US-20250066381-A1 ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS TBXAS1, TASP1, GART CASP1 3617/4885ADRB2 1424/4885ADRB1 1317/4885
US-20250002466-A1 PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF TALDO1, AURKB, PGD CASP1 1372/4885ADRB2 3203/4885ADRB1 1747/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT CASP1 707/4885ADRB2 2293/4885ADRB1 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.